A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients (Q44600268)

4 December 2017

A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients (English)

1 reference

4 December 2017

0 references

1 reference

8

Etsuro Hatano

1 reference

4 December 2017

13

Tsutomu Chiba

1 reference

4 December 2017

Masashi Kanai

1

1 reference

4 December 2017

Yoshihiko Otsuka

2

1 reference

4 December 2017

Kazunori Otsuka

3

1 reference

4 December 2017

Maremi Sato

4

1 reference

4 December 2017

Takafumi Nishimura

5

1 reference

4 December 2017

Yukiko Mori

6

1 reference

4 December 2017

Michiya Kawaguchi

7

1 reference

4 December 2017

Yuzo Kodama

9

1 reference

4 December 2017

Shigemi Matsumoto

10

1 reference

4 December 2017

Yoshiki Murakami

11

1 reference

4 December 2017

Atsushi Imaizumi

12

1 reference

4 December 2017

Jun Nishihira

14

1 reference

4 December 2017

Hiroyuki Shibata

15

1 reference

4 December 2017

language of work or name

1 reference

30 March 2013

1 reference

Cancer Chemotherapy and Pharmacology

4 December 2017

1 reference

4 December 2017

71

1 reference

4 December 2017

1521-1530

1 reference

4 December 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2151-8

4 December 2017

0 references

cites work

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Advanced drug delivery systems of curcumin for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Molecular understanding and modern application of traditional medicines: triumphs and trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Phase II trial of curcumin in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin and gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Clinical trial design for target-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin suppresses growth of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Innovative preparation of curcumin for improved oral bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Cytokines and their relationship to the symptoms and outcome of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Early palliative care for patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

The effects of curcumin on depressive-like behaviors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2151-8

10.1007/S00280-013-2151-8

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference